In a welcome move, Stryker stock saw its Relative Strength Rating improve from 69 to 72 on Monday.
IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves. See if Stryker stock can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is Stryker Stock A Buy?
Stryker stock is building a flat base with a 406.19 entry. This medical stock belongs on your watchlist. This is not the time to buy stocks during a market correction, but build a watchlist of possible emerging leaders once the market trend turns around.
The medical device company posted 16% earnings growth last quarter, while sales growth came in at 11%. Keep an eye out for the company's next round of numbers on or around Apr. 30.
Stryker stock earns the No. 11 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
